David Domzalski - Rockwell Medical Director

RMTI Stock  USD 1.64  0.01  0.61%   

Director

Mr. David T. Domzalski is an Independent Director of Rockwell Medical, Inc. Mr. Domzalski currently serves as President of the U.S. subsidiary of Foamix Pharmaceuticals Inc., a position he has held since April 2014. Prior to his tenure at Foamix, Mr. Domzalski was Vice President of Sales Marketing, at LEO Pharma, Inc. where he led the efforts to design and buildout the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of Leo Pharmas psoriasis franchise from a 2year prescription decline to an annual growth of 26. Mr. Domzalski was responsible for the strategic relaunch of Taclonex Topical Suspension which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Womens Health Urology division of Azur Pharma, where he had full PL responsibility for a startup business unit. Before Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales Marketing for Warner Chilcott, where he directed all commercial efforts for inline brands focused on therapeutic areas of dermatology, womens health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx Tablets for acne since 2017.
Age 49
Tenure 7 years
Address 30142 South Wixom road, Wixom, MI, United States, 48393
Phone248 960 9009
Webhttps://www.rockwellmed.com
Domzalski led the structural design, development and growth of the commercial team at Warner Chilcott from 150 to 500 employees. Earlier in his career, Mr. Domzalski, held senior sales and marketing positions at SanofiSynthelabo, Pharmacia, Dendrite International and ParkeDavis. He earned a Bachelor of Arts in Economics and Political Science from Muhlenberg College.

Rockwell Medical Management Efficiency

The company has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4768) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.2. The current Return On Assets is estimated to decrease to -0.17. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.
The company currently holds 13.44 M in liabilities with Debt to Equity (D/E) ratio of 1.38, which is about average as compared to similar companies. Rockwell Medical has a current ratio of 2.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rockwell Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Rockwell Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rockwell Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rockwell to invest in growth at high rates of return. When we think about Rockwell Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Solomon MayerMicrobot Medical
62
David UrbanFSD Pharma Class
N/A
Donal CarrollFSD Pharma Class
42
Alfred LimEUDA Health Holdings
72
Jun ZhengChina SXT Pharmaceuticals
46
Vladimir KlacarFSD Pharma Class
N/A
Will SantanaPetIQ Inc
45
Moshe ShohamMicrobot Medical
64
Antaine FurlongFSD Pharma Class
40
Martin MaddenMicrobot Medical
57
Yoav WaizerMicrobot Medical
51
James ClarkePetIQ Inc
45
Scott HuffPetIQ Inc
46
Susan SholtisPetIQ Inc
51
Scott BurellMicrobot Medical
52
Mark FirstPetIQ Inc
53
Ronald KennedyPetIQ Inc
71
Yoseph BornsteinMicrobot Medical
65
Gerald GoldbergFSD Pharma Class
70
Prattipati LaxminarainMicrobot Medical
59
Gary MichaelPetIQ Inc
77
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. Rockwell Medical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 300 people. Rockwell Medical (RMTI) is traded on NASDAQ Exchange in USA. It is located in 30142 South Wixom road, Wixom, MI, United States, 48393 and employs 237 people. Rockwell Medical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Rockwell Medical Leadership Team

Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Cooper, Director
David Domzalski, Director
Angus Smith, Principal Financial Officer
Thomas Klema, CFO, Vice President Treasurer, Secretary
Mark Strobeck, CEO President
Marc MD, Chief Officer
James McCarthy, Senior Development
Timothy Chole, Senior Marketing
Mark Ravich, Director
Michael DeYoung, Vice President - Operations
Kenneth Holt, Independent Director
Benjamin Wolin, Chairman of the Board
Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller
Megan Timmins, Chief VP
Patrick Bagley, Independent Director
David Kull, Principal Accounting Officer
Jim McCarthy, Senior Vice President - Corporate and Business Development
Jason Finkelstein, Investor Representative
Ajay Gupta, Chief Scientific Officer
Ronald Boyd, Independent Director
Lisa Colleran, Director
Jesse Neri, Senior Finance
Charlie Shiner, Vice President of Marketing
Raymond Pratt, Chief Medical Officer
Robin Smith, Director
Robert Chioini, Founder, Chairman of The Board and CEO
Heather Hunter, Senior Officer
Michael Rice, Co-Founder, LifeSci Advisors, LLC
Stuart Paul, CEO, Director

Rockwell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Rockwell Stock analysis

When running Rockwell Medical's price analysis, check to measure Rockwell Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rockwell Medical is operating at the current time. Most of Rockwell Medical's value examination focuses on studying past and present price action to predict the probability of Rockwell Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rockwell Medical's price. Additionally, you may evaluate how the addition of Rockwell Medical to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is Rockwell Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
3.585
Quarterly Revenue Growth
0.144
Return On Assets
(0.08)
Return On Equity
(0.48)
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.